AI for predicting malignancy risk of pulmonary nodules detected at CT screening

Written By :  Hina Zahid
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-05-20 03:30 GMT   |   Update On 2021-05-20 03:30 GMT

Denmark: An artificial intelligence (AI) program showed excellent performance than thoracic radiologists in predicting malignancy risk of pulmonary nodules detected at screening CT, according to a recent study in the journal Radiology.

The results suggest that this deep learning algorithm has the potential to provide reliable and reproducible malignancy risk scores for clinicians, which may help optimize management in lung cancer screening.

Lung cancer is the leading cause of cancer death worldwide, with an estimated 1.8 million deaths in 2020, according to the World Health Organization. Low-dose chest CT is used to screen people at a high risk of lung cancer, such as longtime smokers. It has been shown to significantly reduce lung cancer mortality, primarily by helping to detect cancers at an early stage when they are easier to treat successfully.

Advertisement

While lung cancer typically shows up as pulmonary nodules on CT images, most nodules are benign and do not require further clinical workup. Accurately distinguishing between benign and malignant nodules is therefore crucial to catch cancers early.

For the new study, researchers developed an algorithm for lung nodule assessment using deep learning, an AI application capable of finding certain patterns in imaging data. The researchers trained the algorithm on CT images of more than 16,000 nodules, including 1,249 malignancies, from the National Lung Screening Trial. They validated the algorithm on three large sets of imaging data of nodules from the Danish Lung Cancer Screening Trial.

The deep learning algorithm delivered excellent results, outperforming the established Pan-Canadian Early Detection of Lung Cancer model for lung nodule malignancy risk estimation. It performed comparably to 11 clinicians, including four thoracic radiologists, five radiology residents and two pulmonologists.

"The algorithm may aid radiologists in accurately estimating the malignancy risk of pulmonary nodules," said the study's first author, Kiran Vaidhya Venkadesh, a Ph.D. candidate with the Diagnostic Image Analysis Group at Radboud University Medical Center in Nijmegen, the Netherlands. "This may help in optimizing follow-up recommendations for lung cancer screening participants."

The algorithm potentially brings several additional benefits to the clinic, the researchers said.

"As it does not require manual interpretation of nodule imaging characteristics, the proposed algorithm may reduce the substantial interobserver variability in CT interpretation," said senior author Colin Jacobs, Ph.D., assistant professor in the Department of Medical Imaging at Radboud University Medical Center in Nijmegen. "This may lead to fewer unnecessary diagnostic interventions, lower radiologists' workload and reduce costs of lung cancer screening."

The researchers plan to continue improving the algorithm by incorporating clinical parameters like age, sex and smoking history.

They are also working on a deep learning algorithm that takes multiple CT examinations as input. The current algorithm is highly suitable for analyzing nodules at the initial, or baseline, screening, but for nodules detected at subsequent screenings, growth and appearance in comparison to the previous CT are important.

Dr. Jacobs and colleagues have developed other algorithms to reliably extract imaging features from the chest CT related to chronic obstructive pulmonary diseases and cardiovascular diseases. They will be investigating how to effectively integrate these imaging features into the current algorithm.

Reference:

The study titled, "Deep Learning for Malignancy Risk Estimation of Pulmonary Nodules Detected at Low-Dose Screening CT," is published in the journal Radiology.

DOI: https://pubs.rsna.org/doi/10.1148/radiol.2021204433

Tags:    
Article Source : Radiology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News